ID   HCV-29
AC   CVCL_8228
SY   HCV.29; HCV 29; HCV29
DR   cancercelllines; CVCL_8228
DR   Cosmic; 925834
DR   Cosmic; 1286002
DR   Cosmic; 1927313
DR   Cosmic; 2212692
DR   Wikidata; Q54882078
RX   PubMed=3708594;
RX   PubMed=3800330;
RX   PubMed=6244232;
RX   PubMed=7905254;
RX   PubMed=8900435;
RX   PubMed=11416159;
RX   PubMed=15846775;
RX   PubMed=23401075;
RX   PubMed=24035680;
RX   PubMed=29732388;
RX   PubMed=30193179;
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (PubMed=23401075).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
CC   Sequence variation: Mutation; HGNC; 12362; TSC1; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000048808; Zygosity=Homozygous (PubMed=23401075).
CC   Caution: HCV-29 is said to be a non-malignant bladder epithelial cell line. But due to the fact that it is immortal and contains AKT and BRAF mutations we consider it to be a bladder carcinoma cell line.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): PubMed=11416159
ST   Amelogenin: X,Y
ST   D18S51: 13,14
ST   D21S11: 28,29
ST   D8S1179: 13,16
ST   FGA: 22
ST   TH01: 6,8
ST   vWA: 19,21
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Adult
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 19
//
RX   PubMed=3708594;
RA   Masters J.R.W., Hepburn P.J., Walker L., Highman W.J.,
RA   Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N.,
RA   Franks L.M.;
RT   "Tissue culture model of transitional cell carcinoma: characterization
RT   of twenty-two human urothelial cell lines.";
RL   Cancer Res. 46:3630-3636(1986).
//
RX   PubMed=3800330;
RA   Debiec-Rychter M., Christensen B., Kieler J., Wang C.Y.;
RT   "Chromosomal characterization and isoenzyme pattern of non-malignant
RT   and malignant human urothelial cell lines.";
RL   Anticancer Res. 6:1237-1244(1986).
//
RX   PubMed=6244232;
RA   Williams R.D.;
RT   "Human urologic cancer cell lines.";
RL   Invest. Urol. 17:359-363(1980).
//
RX   PubMed=7905254;
RA   Christensen B., Hansen C., Kieler J., Schmidt J.;
RT   "Identity of non-malignant human urothelial cell lines classified as
RT   transformation grade I (TGrI) and II (TGrII).";
RL   Anticancer Res. 13:2187-2191(1993).
//
RX   PubMed=8900435; DOI=10.1002/(SICI)1097-0215(19961009)68:2<239::AID-IJC17>3.0.CO;2-5;
RA   Klopocki A.G., Krop-Watorek A., Dus D., Ugorski M.;
RT   "Adhesion of human uroepithelial cells to E-selectin: possible
RT   involvement of sialosyl LewisA-ganglioside.";
RL   Int. J. Cancer 68:239-244(1996).
//
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
//
RX   PubMed=15846775; DOI=10.1002/gcc.20166;
RA   Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M.,
RA   Knowles M.A.;
RT   "Assessment by M-FISH of karyotypic complexity and cytogenetic
RT   evolution in bladder cancer in vitro.";
RL   Genes Chromosomes Cancer 43:315-328(2005).
//
RX   PubMed=23401075; DOI=10.1002/path.4176;
RA   Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L.,
RA   Kwiatkowski D.J.;
RT   "TSC1 involvement in bladder cancer: diverse effects and therapeutic
RT   implications.";
RL   J. Pathol. 230:17-27(2013).
//
RX   PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057;
RA   Hurst C.D., Platt F.M., Knowles M.A.;
RT   "Comprehensive mutation analysis of the TERT promoter in bladder
RT   cancer and detection of mutations in voided urine.";
RL   Eur. Urol. 65:367-369(2014).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//
RX   PubMed=30193179; DOI=10.1016/j.jmbbm.2018.08.036;
RA   Raczkowska J., Prauzner-Bechcicki S.;
RT   "Discrimination between HCV29 and T24 by controlled proliferation of
RT   cells co-cultured on substrates with different elasticity.";
RL   J. Mech. Behav. Biomed. Mater. 88:217-222(2018).
//